MCID: LNG003
MIFTS: 40

Lung Carcinoma in Situ

Categories: Cancer diseases, Genetic diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lung Carcinoma in Situ

MalaCards integrated aliases for Lung Carcinoma in Situ:

Name: Lung Carcinoma in Situ 11 14

Classifications:



External Ids:

Disease Ontology 11 DOID:8800
ICD9CM 34 231.2
SNOMED-CT 68 189262006
ICD10 31 D02.2
UMLS 71 C0154071

Summaries for Lung Carcinoma in Situ

Disease Ontology: 11 An in situ carcinoma that is located in the lung.

MalaCards based summary: Lung Carcinoma in Situ is related to lung squamous cell carcinoma and pulmonary adenocarcinoma in situ. An important gene associated with Lung Carcinoma in Situ is OR9A4 (Olfactory Receptor Family 9 Subfamily A Member 4), and among its related pathways/superpathways are Disease and TGF-Beta Pathway. Affiliated tissues include lung, and related phenotypes are Decreased viability and neoplasm

Related Diseases for Lung Carcinoma in Situ

Diseases in the Lung Cancer family:

Lung Carcinoma in Situ

Diseases related to Lung Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 350)
# Related Disease Score Top Affiliating Genes
1 lung squamous cell carcinoma 29.4 TP53 KRAS HRAS EGFR ALK AKT1
2 pulmonary adenocarcinoma in situ 29.1 TP53 SLC18A3 SFTPC NKX2-1 MIR4796 KRT7
3 trachea carcinoma in situ 10.3 KRAS HRAS
4 common bile duct neoplasm 10.3 KRAS HRAS
5 ampulla of vater benign neoplasm 10.3 KRAS HRAS
6 hepatic flexure cancer 10.3 KRAS HRAS
7 descending colon cancer 10.3 KRAS HRAS
8 pancreatic mucinous cystadenoma 10.3 KRAS HRAS
9 transverse colon cancer 10.3 KRAS HRAS
10 noonan syndrome-like disorder with loose anagen hair 1 10.3 KRAS HRAS
11 heart leiomyosarcoma 10.3 EGFR ALK
12 esophagus verrucous carcinoma 10.3 TP53 EGFR
13 frontal lobe neoplasm 10.3 TP53 EGFR
14 cecum adenocarcinoma 10.3 KRAS HRAS
15 malignant struma ovarii 10.3 NKX2-1 HRAS
16 acneiform dermatitis 10.3 KRAS HRAS EGFR
17 vulvar keratinizing squamous cell carcinoma 10.3 TP53 ALK
18 spinal cord oligodendroglioma 10.3 TP53 EGFR
19 dermatopathia pigmentosa reticularis 10.2 KRAS HRAS EGFR
20 occipital lobe neoplasm 10.2 EML4 ALK
21 pulmonary large cell neuroendocrine carcinoma 10.2 NKX2-1 ALK
22 epithelioid inflammatory myofibroblastic sarcoma 10.2 EML4 ALK
23 laryngeal neuroendocrine tumor 10.2 TP53 NKX2-1
24 larynx squamous papilloma 10.2 TP53 HRAS
25 arteriovenous malformations of the brain 10.2 KRAS HRAS EGFR
26 papillary squamous carcinoma 10.2 KRT7 EGFR
27 nasal cavity adenocarcinoma 10.2 KRT7 HRAS
28 benign breast adenomyoepithelioma 10.2 KRT7 EGFR
29 pancreatic acinar cell adenocarcinoma 10.2 KRAS HRAS
30 lung combined large cell neuroendocrine carcinoma 10.2 EML4 ALK
31 breast malignant phyllodes tumor 10.2 TP53 EGFR
32 breast adenomyoepithelioma 10.2 KRT7 HRAS
33 ureter adenocarcinoma 10.2 NKX2-1 KRT7
34 mucinous bronchioloalveolar adenocarcinoma 10.2 NKX2-1 KRT7
35 rectosigmoid junction neoplasm 10.2 KRT7 KRAS
36 breast myoepithelial neoplasm 10.2 KRT7 HRAS
37 aortic malignant tumor 10.2 NKX2-1 KRT7
38 oculoectodermal syndrome 10.2 KRAS HRAS
39 liver angiosarcoma 10.2 TP53 KRAS HRAS
40 signet ring lung adenocarcinoma 10.2 EML4 EGFR ALK
41 large cell carcinoma with rhabdoid phenotype 10.2 TP53 KRAS HRAS
42 pancreatic signet ring cell adenocarcinoma 10.2 TP53 KRAS HRAS
43 adult malignant schwannoma 10.2 TP53 HRAS EGFR
44 ovarian carcinosarcoma 10.2 TP53 KRAS HRAS
45 vulva squamous cell carcinoma 10.2 TP53 HRAS EGFR
46 plexiform neurofibroma 10.2 TP53 HRAS EGFR
47 endometrioid ovary carcinoma 10.2 TP53 KRAS HRAS
48 ureter small cell carcinoma 10.2 NKX2-1 KRT7
49 lip and oral cavity cancer 10.2 TP53 HRAS EGFR
50 syringocystadenoma papilliferum 10.2 KRT7 HRAS

Graphical network of the top 20 diseases related to Lung Carcinoma in Situ:



Diseases related to Lung Carcinoma in Situ

Symptoms & Phenotypes for Lung Carcinoma in Situ

GenomeRNAi Phenotypes related to Lung Carcinoma in Situ according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.72 EGFR HRAS KRAS
2 Decreased viability GR00055-A-2 9.72 EGFR HRAS KRAS
3 Decreased viability GR00055-A-3 9.72 KRAS
4 Decreased viability GR00106-A-0 9.72 KRAS
5 Decreased viability GR00221-A-1 9.72 AKT1 ALK EGFR HRAS KRAS
6 Decreased viability GR00221-A-2 9.72 AKT1 HRAS KRAS
7 Decreased viability GR00221-A-3 9.72 AKT1 HRAS
8 Decreased viability GR00221-A-4 9.72 AKT1 ALK EGFR
9 Decreased viability GR00249-S 9.72 AKT1 ALK
10 Decreased viability GR00301-A 9.72 KRAS
11 Decreased viability GR00381-A-1 9.72 KRAS

MGI Mouse Phenotypes related to Lung Carcinoma in Situ:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.01 AKT1 ALK EGFR HRAS KRAS NKX2-1
2 normal MP:0002873 9.97 AKT1 ALK EGF EGFR HRAS KRAS
3 endocrine/exocrine gland MP:0005379 9.91 AKT1 ALK DELE1 EGF EGFR HRAS
4 no phenotypic analysis MP:0003012 9.87 EGFR HRAS KRAS NKX2-1 SFTPC SLC18A3
5 respiratory system MP:0005388 9.76 AKT1 ALK EGFR HRAS KRAS NKX2-1
6 reproductive system MP:0005389 9.7 AKT1 ALK CALR3 DELE1 EGF EGFR
7 skeleton MP:0005390 9.28 AKT1 ALK DELE1 EGFR HRAS KRAS

Drugs & Therapeutics for Lung Carcinoma in Situ

Search Clinical Trials, NIH Clinical Center for Lung Carcinoma in Situ

Genetic Tests for Lung Carcinoma in Situ

Anatomical Context for Lung Carcinoma in Situ

Organs/tissues related to Lung Carcinoma in Situ:

FMA: Lung
MalaCards : Lung

Publications for Lung Carcinoma in Situ

Articles related to Lung Carcinoma in Situ:

# Title Authors PMID Year
1
Role of bronchoscopy in management of central squamous cell lung carcinoma in situ. 62
31516900 2019
2
Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. 62
30664780 2019
3
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers. 62
26725182 2016
4
miR-101 DNA copy loss is a prominent subtype specific event in lung cancer. 62
21849855 2011
5
Diagnosis and treatment of early lung cancer: as it stands today. 62
16088482 2004
6
Endoscopic treatment of early-stage lung cancer. 62
10740659 2000
7
[The prognostic significance of the direct effect in the conservative treatment of small-cell lung cancer]. 62
1658530 1991

Variations for Lung Carcinoma in Situ

Cosmic variations for Lung Carcinoma in Situ:

8 (show top 50) (show all 1540)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM102042323 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8009A>G p.? 16:72958974-72958974 4
2 COSM87291734 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 4
3 COSM102040476 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8037G>T p.? 16:72959002-72959002 4
4 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 4
5 COSM87290218 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 4
6 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 4
7 COSM126973051 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.770C>T p.P257L 11:102229729-102229729 4
8 COSM145028029 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1154C>T p.P385L 11:102229729-102229729 4
9 COSM128452039 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 4
10 COSM85237448 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1304C>T p.P435L 11:102229729-102229729 4
11 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 4
12 COSM127997731 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1256C>T p.P419L 11:102229729-102229729 4
13 COSM133274224 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1268C>T p.P423L 11:102229729-102229729 4
14 COSM90948266 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1202C>T p.P401L 11:102229729-102229729 4
15 COSM108017622 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 4
16 COSM95166535 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 4
17 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 4
18 COSM105839764 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 4
19 COSM106337415 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 4
20 COSM103711109 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1036A>C p.I346L 22:41653558-41653558 4
21 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 4
22 COSM134125623 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1114A>G p.M372V 19:43546970-43546970 4
23 COSM100781761 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.724A>T p.K242* 11:32392044-32392044 4
24 COSM111539040 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 4
25 COSM149728755 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 4
26 COSM130518653 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.673A>T p.K225* 11:32392044-32392044 4
27 COSM113475703 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 4
28 COSM111529696 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 4
29 COSM113484991 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 4
30 COSM147414475 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 4
31 COSM149739953 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 4
32 COSM148580942 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 4
33 COSM148593279 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 4
34 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 4
35 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 4
36 COSM147426277 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 4
37 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 4
38 COSM104050903 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 4
39 COSM105123686 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 4
40 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 4
41 COSM102763785 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 4
42 COSM99767946 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 4
43 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 4
44 COSM121848752 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 4
45 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 4
46 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 4
47 COSM99795256 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 4
48 COSM143996084 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1620C>G p.F540L 19:4947122-4947122 4
49 COSM143964403 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1428C>G p.F476L 19:4947122-4947122 4
50 COSM145430147 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1467C>G p.F489L 19:4947122-4947122 4

Expression for Lung Carcinoma in Situ

Search GEO for disease gene expression data for Lung Carcinoma in Situ.

Pathways for Lung Carcinoma in Situ

Pathways related to Lung Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.75 TPST1 TP53 SFTPC KRAS HRAS EML4
2
Show member pathways
13.53 TP53 KRAS HRAS EGFR EGF ALK
3
Show member pathways
13.43 TP53 KRAS HRAS EGFR EGF ALK
4
Show member pathways
13.39 KRAS HRAS EML4 EGFR EGF ALK
5
Show member pathways
13.31 KRAS HRAS EGFR EGF ALK AKT1
6
Show member pathways
13.27 KRAS HRAS EGFR EGF ALK AKT1
7
Show member pathways
13.09 TP53 KRAS HRAS EGFR EGF AKT1
8
Show member pathways
13.07 AKT1 ALK EGF EGFR HRAS KRAS
9
Show member pathways
12.98 KRAS HRAS EGFR EGF AKT1
10
Show member pathways
12.95 TP53 KRAS HRAS EGFR EGF AKT1
11 12.79 AKT1 ALK EGF EGFR HRAS KRAS
12 12.72 TP53 HRAS EGFR EGF AKT1
13
Show member pathways
12.7 KRAS HRAS EGFR EGF AKT1
14
Show member pathways
12.69 KRAS HRAS EGFR EGF AKT1
15
Show member pathways
12.62 TP53 KRAS HRAS EGFR EGF AKT1
16
Show member pathways
12.62 TP53 KRAS HRAS EGFR EGF AKT1
17
Show member pathways
12.6 TP53 KRAS HRAS EGFR AKT1
18
Show member pathways
12.44 KRAS HRAS EGFR EGF AKT1
19
Show member pathways
12.42 KRAS HRAS EGFR EGF ALK
20
Show member pathways
12.4 TP53 KRAS HRAS EGFR AKT1
21
Show member pathways
12.39 TP53 KRAS HRAS EGFR EGF AKT1
22
Show member pathways
12.38 TP53 KRAS HRAS EML4 EGFR EGF
23
Show member pathways
12.37 KRAS HRAS EGFR EGF AKT1
24
Show member pathways
12.36 AKT1 EGF EGFR HRAS
25
Show member pathways
12.33 TP53 KRAS HRAS EGFR EGF AKT1
26 12.32 HRAS EGFR EGF AKT1
27 12.28 KRAS HRAS EGFR AKT1
28
Show member pathways
12.28 KRAS HRAS EGFR EGF
29 12.27 TP53 KRAS HRAS EGFR EGF AKT1
30
Show member pathways
12.24 KRAS HRAS EGFR AKT1
31 12.2 TP53 KRAS HRAS AKT1
32
Show member pathways
12.2 TP53 KRAS HRAS AKT1
33
Show member pathways
12.19 HRAS EGFR EGF AKT1
34
Show member pathways
12.19 TP53 KRAS HRAS EGFR AKT1
35 12.16 AKT1 EGFR KRAS TP53
36 12.15 TP53 KRAS EGFR EGF AKT1
37
Show member pathways
12.14 HRAS EGFR EGF AKT1
38 12.12 TP53 KRAS EGFR AKT1
39
Show member pathways
12.11 EGF EGFR HRAS KRAS
40
Show member pathways
12.11 KRAS HRAS EGFR EGF AKT1
41
Show member pathways
12.08 KRAS HRAS EGFR EGF
42
Show member pathways
12.01 TP53 EGFR AKT1
43
Show member pathways
11.99 KRAS HRAS EGFR EGF AKT1
44 11.97 AKT1 EGFR HRAS KRAS
45 11.93 TP53 KRAS HRAS
46
Show member pathways
11.88 KRAS HRAS EGFR EGF
47
Show member pathways
11.88 AKT1 EGF EGFR HRAS KRAS
48
Show member pathways
11.82 KRAS HRAS AKT1
49 11.79 AKT1 EGF TP53
50
Show member pathways
11.77 AKT1 HRAS KRAS TP53

GO Terms for Lung Carcinoma in Situ

Biological processes related to Lung Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.9 TP53 NKX2-1 KRAS HRAS EGF AKT1
2 regulation of cell population proliferation GO:0042127 9.88 TP53 HRAS EGFR ALK
3 epidermal growth factor receptor signaling pathway GO:0007173 9.8 EGFR EGF AKT1
4 ERBB2-EGFR signaling pathway GO:0038134 9.73 EGFR EGF
5 positive regulation of protein tyrosine kinase activity GO:0061098 9.65 ALK EGF EGFR
6 positive regulation of miRNA maturation GO:1903800 9.37 TP53 EGFR
7 response to UV-A GO:0070141 9.26 EGFR AKT1
8 cell population proliferation GO:0008283 9.1 TP53 KRAS EGFR EGF AKT1

Molecular functions related to Lung Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nitric-oxide synthase regulator activity GO:0030235 8.92 EGFR AKT1

Sources for Lung Carcinoma in Situ

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....